Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial

Area of Science:

• Oncology
• Medical Research
• Clinical Trials

Background:

• Recurrent/metastatic nasopharyngeal carcinoma (NPC) presents limited therapeutic avenues post-chemotherapy and programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) inhibitor failure.
• Patients with advanced NPC often face a poor prognosis after exhausting standard treatment options.

Purpose of the Study:

• To evaluate the efficacy and safety of becotatug vedotin versus chemotherapy in patients with recurrent/metastatic NPC.
• To compare objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) between treatment arms.

Main Methods:

• A multicenter, open-label, randomized trial involving 173 patients with heavily pretreated recurrent/metastatic NPC.
• Participants were randomized 1:1 to receive either becotatug vedotin (anti-EGFR ADC) or standard chemotherapy (capecitabine/docetaxel).
• Co-primary endpoints included ORR, PFS, and OS, assessed by an independent review committee.

Main Results:

• Becotatug vedotin demonstrated a significantly higher ORR (30.2% vs 11.5%, P=0.003) compared to chemotherapy.
• Median PFS was significantly improved with becotatug vedotin (5.82 vs 2.83 months; HR=0.63, P=0.01), indicating a reduced risk of progression or death.
• Interim overall survival data showed a median OS of 17.08 months for becotatug vedotin versus 11.99 months for chemotherapy (HR=0.73, P=0.15).

Conclusions:

• Becotatug vedotin significantly enhances ORR and PFS in heavily pretreated, immunotherapy-exposed recurrent/metastatic NPC patients.
• The anti-EGFR antibody-drug conjugate showed comparable safety to chemotherapy.
• Encouraging, though immature, overall survival results suggest potential benefit for becotatug vedotin.